In addition, PHGDH was similarly overexpressed in high-risk MYCN-amplified MBSHH, but not in better prognosis MYCN-amplified MBGRP4, suggesting the pathogenicity of MYC in medulloblastoma subtypes correlates with upregulation of PHGDH and worse prognosis, and identifying a further medulloblastoma subgroup which may benefit from PHGDH targeting. The gene discussed is MYC; the disease is medulloblastoma.